|
x
|
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
|
27-2004382
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
11055 Flintkote Avenue, Suite B, San Diego, California
|
|
92121
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
|
|
(858) 952-7570
|
||
(Registrant’s telephone number, including area code)
|
|
Large accelerated filer
|
o
|
|
|
Accelerated filer
|
o
|
|
|
|
|
|
|
|
|
|
|
Non-accelerated filer
|
o
|
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Emerging growth company
|
o
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2018
|
|
December 31, 2017
|
||||
Assets
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
18,485,950
|
|
|
$
|
8,225,764
|
|
Short-term investment
|
31,500
|
|
|
—
|
|
||
Accounts receivable and unbilled receivable
|
124,082
|
|
|
77,095
|
|
||
Prepaid expenses and other current assets
|
1,001,840
|
|
|
1,165,828
|
|
||
Total current assets
|
19,643,372
|
|
|
9,468,687
|
|
||
Property and equipment, net
|
1,803,921
|
|
|
2,426,312
|
|
||
Other assets
|
320,749
|
|
|
389,942
|
|
||
Total Assets
|
$
|
21,768,042
|
|
|
$
|
12,284,941
|
|
|
|
|
|
||||
Liabilities and Stockholders’ Equity
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
565,413
|
|
|
$
|
825,244
|
|
Accrued expenses
|
2,303,366
|
|
|
1,454,587
|
|
||
Deferred rent, current portion
|
349,565
|
|
|
334,424
|
|
||
Current portion of long-term debt
|
—
|
|
|
1,331,515
|
|
||
Total current liabilities
|
3,218,344
|
|
|
3,945,770
|
|
||
Derivative financial instruments—warrants
|
67,847
|
|
|
649,387
|
|
||
Deferred rent, net of current portion
|
1,004,689
|
|
|
1,183,677
|
|
||
Total Liabilities
|
4,290,880
|
|
|
5,778,834
|
|
||
|
|
|
|
||||
Commitments and contingencies (Note 8)
|
|
|
|
|
|
||
|
|
|
|
||||
Stockholders’ equity
|
|
|
|
||||
Preferred stock, $0.001 par value, 20,000,000 shares authorized; 277,100 designated as Series A Convertible Preferred Stock; 60,600 shares outstanding at June 30, 2018 and December 31, 2017 with liquidation preference of $606,000 at June 30, 2018 and December 31, 2017; 8,860 designated as Series B Convertible Preferred Stock; 5,650 and 0 shares outstanding at June 30, 2018 and December 31, 2017, respectively
|
66
|
|
|
60
|
|
||
Common stock, $0.0001 par value, 150,000,000 shares authorized; 17,305,004 and 4,399,299 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively
|
7,173
|
|
|
5,279
|
|
||
Additional paid-in capital
|
201,720,972
|
|
|
179,546,954
|
|
||
Accumulated deficit
|
(184,251,049
|
)
|
|
(173,046,186
|
)
|
||
Total stockholders’ equity
|
17,477,162
|
|
|
6,506,107
|
|
||
Total liabilities and stockholders’ equity
|
$
|
21,768,042
|
|
|
$
|
12,284,941
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2018
|
|
2017
|
|
2018
|
|
2017
|
||||||||
Revenues:
|
|
|
|
|
|
|
|
||||||||
Royalties
|
$
|
52,423
|
|
|
$
|
44,810
|
|
|
$
|
101,478
|
|
|
$
|
110,636
|
|
Diagnostic services
|
39,345
|
|
|
55,501
|
|
|
79,347
|
|
|
84,363
|
|
||||
Clinical research services
|
20,045
|
|
|
1,700
|
|
|
31,124
|
|
|
2,050
|
|
||||
Total revenues
|
111,813
|
|
|
102,011
|
|
|
211,949
|
|
|
197,049
|
|
||||
Costs and expenses:
|
|
|
|
|
|
|
|
||||||||
Cost of revenues
|
204,436
|
|
|
338,203
|
|
|
570,780
|
|
|
954,629
|
|
||||
Research and development
|
1,952,767
|
|
|
981,715
|
|
|
3,836,605
|
|
|
5,261,545
|
|
||||
Selling, general and administrative
|
2,150,871
|
|
|
4,674,152
|
|
|
4,655,848
|
|
|
8,278,776
|
|
||||
Restructuring charges (benefit)
|
243,335
|
|
|
(3,806
|
)
|
|
243,335
|
|
|
1,715,998
|
|
||||
Total operating expenses
|
4,551,409
|
|
|
5,990,264
|
|
|
9,306,568
|
|
|
16,210,948
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Loss from operations
|
(4,439,596
|
)
|
|
(5,888,253
|
)
|
|
(9,094,619
|
)
|
|
(16,013,899
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Net interest income (expense)
|
35,277
|
|
|
(431,871
|
)
|
|
32,812
|
|
|
(861,268
|
)
|
||||
Gain (loss) from change in fair value of derivative financial instruments—warrants
|
711,229
|
|
|
(71,428
|
)
|
|
581,540
|
|
|
484,078
|
|
||||
Gain (loss) on extinguishment of debt
|
17,974
|
|
|
(1,655,825
|
)
|
|
17,974
|
|
|
(1,655,825
|
)
|
||||
Other (loss) income, net
|
(71,839
|
)
|
|
1,566
|
|
|
(70,839
|
)
|
|
1,566
|
|
||||
Net loss
|
(3,746,955
|
)
|
|
(8,045,811
|
)
|
|
(8,533,132
|
)
|
|
(18,045,348
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Preferred stock dividend payable on Series A Convertible Preferred Stock
|
(6,060
|
)
|
|
(6,060
|
)
|
|
(12,120
|
)
|
|
(12,120
|
)
|
||||
Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance
|
(2,769,533
|
)
|
|
—
|
|
|
(2,769,533
|
)
|
|
—
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Net loss attributable to common stockholders
|
$
|
(6,522,548
|
)
|
|
$
|
(8,051,871
|
)
|
|
$
|
(11,314,785
|
)
|
|
$
|
(18,057,468
|
)
|
|
|
|
|
|
|
|
|
||||||||
Net loss per common share — basic
|
$
|
(0.88
|
)
|
|
$
|
(3.12
|
)
|
|
$
|
(1.88
|
)
|
|
$
|
(7.00
|
)
|
Net loss per common share — diluted
|
$
|
(0.88
|
)
|
|
$
|
(3.12
|
)
|
|
$
|
(1.88
|
)
|
|
$
|
(7.00
|
)
|
|
|
|
|
|
|
|
|
||||||||
Weighted-average shares outstanding — basic
|
7,423,463
|
|
|
2,582,645
|
|
|
6,026,345
|
|
|
2,581,372
|
|
||||
Weighted-average shares outstanding — diluted
|
7,423,463
|
|
|
2,582,645
|
|
|
6,026,345
|
|
|
2,581,372
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2018
|
|
2017
|
|
2018
|
|
2017
|
||||||||
Net loss
|
$
|
(3,746,955
|
)
|
|
$
|
(8,045,811
|
)
|
|
$
|
(8,533,132
|
)
|
|
$
|
(18,045,348
|
)
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
|
||||||||
Foreign currency translation loss
|
—
|
|
|
(9,543
|
)
|
|
—
|
|
|
(11,942
|
)
|
||||
Unrealized gain or reversal of previous losses on securities available-for-sale
|
—
|
|
|
9,519
|
|
|
—
|
|
|
9,065
|
|
||||
Total other comprehensive loss
|
—
|
|
|
(24
|
)
|
|
—
|
|
|
(2,877
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Total comprehensive loss
|
(3,746,955
|
)
|
|
(8,045,835
|
)
|
|
(8,533,132
|
)
|
|
(18,048,225
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Preferred stock dividend payable on Series A Convertible Preferred Stock
|
(6,060
|
)
|
|
(6,060
|
)
|
|
(12,120
|
)
|
|
(12,120
|
)
|
||||
Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance
|
(2,769,533
|
)
|
|
—
|
|
|
(2,769,533
|
)
|
|
—
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Comprehensive loss attributable to common stockholders
|
$
|
(6,522,548
|
)
|
|
$
|
(8,051,895
|
)
|
|
$
|
(11,314,785
|
)
|
|
$
|
(18,060,345
|
)
|
|
Preferred Stock
Shares |
|
Preferred Stock
Amount |
|
Common Stock
Shares |
|
Common Stock
Amount |
|
Additional
Paid-In Capital |
|
Accumulated Deficit
|
|
Total
Stockholders’ Equity |
||||||||||||
Balance, January 1, 2018
|
60,600
|
|
|
$
|
60
|
|
|
4,399,299
|
|
|
$
|
5,279
|
|
|
$
|
179,546,954
|
|
|
$
|
(173,046,186
|
)
|
|
$
|
6,506,107
|
|
Stock-based compensation
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,627,431
|
|
|
—
|
|
|
1,627,431
|
|
|||||
Sale of common stock and warrants, net of expenses
|
—
|
|
|
—
|
|
|
9,140,000
|
|
|
914
|
|
|
11,778,611
|
|
|
—
|
|
|
11,779,525
|
|
|||||
Sale of Series B Convertible Preferred Stock, net of expenses
|
8,860
|
|
|
9
|
|
|
—
|
|
|
—
|
|
|
4,386,753
|
|
|
—
|
|
|
4,386,762
|
|
|||||
Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,769,533
|
|
|
(2,769,533
|
)
|
|
—
|
|
|||||
Issuance of common stock upon exercise of warrants
|
—
|
|
|
—
|
|
|
473,497
|
|
|
569
|
|
|
1,612,098
|
|
|
—
|
|
|
1,612,667
|
|
|||||
Issuance of common stock upon vesting of restricted stock units
|
—
|
|
|
—
|
|
|
75,400
|
|
|
90
|
|
|
(90
|
)
|
|
—
|
|
|
—
|
|
|||||
Issuance of common stock upon conversion of Series B Convertible Preferred Stock
|
(3,210
|
)
|
|
(3
|
)
|
|
3,210,000
|
|
|
321
|
|
|
(318
|
)
|
|
—
|
|
|
—
|
|
|||||
Preferred stock dividend payable on Series A Convertible Preferred Stock
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(12,120
|
)
|
|
(12,120
|
)
|
|||||
Issuance of common stock for share rounding as a result of reverse stock split
|
—
|
|
|
—
|
|
|
6,808
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Cumulative adjustment upon adoption of ASC 606
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
109,922
|
|
|
109,922
|
|
|||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(8,533,132
|
)
|
|
(8,533,132
|
)
|
|||||
Balance, June 30, 2018
|
66,250
|
|
|
$
|
66
|
|
|
17,305,004
|
|
|
$
|
7,173
|
|
|
$
|
201,720,972
|
|
|
$
|
(184,251,049
|
)
|
|
$
|
17,477,162
|
|
|
Six Months Ended June 30,
|
||||||
|
2018
|
|
2017
|
||||
Operating activities
|
|
|
|
||||
Net loss
|
$
|
(8,533,132
|
)
|
|
$
|
(18,045,348
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
||||
Loss on disposal of assets
|
198,099
|
|
|
28,097
|
|
||
Impairment loss
|
187,500
|
|
|
485,000
|
|
||
Depreciation and amortization
|
483,495
|
|
|
645,962
|
|
||
Stock based compensation expense
|
1,627,431
|
|
|
1,696,184
|
|
||
(Gain) loss on extinguishment of debt
|
(17,974
|
)
|
|
1,655,825
|
|
||
Accretion of final fee premium
|
—
|
|
|
293,614
|
|
||
Amortization of discount on debt
|
—
|
|
|
113,780
|
|
||
Net realized loss on short-term investments
|
—
|
|
|
6,400
|
|
||
Amortization of premiums on short-term investments
|
—
|
|
|
9,230
|
|
||
Deferred rent
|
(163,847
|
)
|
|
(136,776
|
)
|
||
Interest income accrued on short-term investments
|
—
|
|
|
(90,330
|
)
|
||
Change in fair value of derivative financial instruments—warrants
|
(581,540
|
)
|
|
(484,078
|
)
|
||
Changes in operating assets and liabilities:
|
|
|
|
||||
Increase in other assets
|
(199,743
|
)
|
|
—
|
|
||
Decrease (increase) in accounts receivable and unbilled receivable
|
62,935
|
|
|
(56,985
|
)
|
||
Decrease in prepaid expenses and other current assets
|
191,321
|
|
|
243,571
|
|
||
Increase in accounts payable and accrued expenses
|
638,701
|
|
|
280,520
|
|
||
Net cash used in operating activities
|
(6,106,754
|
)
|
|
(13,355,334
|
)
|
||
|
|
|
|
||||
Investing activities:
|
|
|
|
||||
Capital expenditures, net
|
(5,100
|
)
|
|
(20,738
|
)
|
||
Maturities of short-term investments
|
—
|
|
|
16,431,837
|
|
||
Purchases of short-term investments
|
(31,500
|
)
|
|
(8,804,604
|
)
|
||
Sales of short-term investments
|
—
|
|
|
16,434,553
|
|
||
Net cash (used in) provided by investing activities
|
(36,600
|
)
|
|
24,041,048
|
|
||
|
|
|
|
||||
Financing activities:
|
|
|
|
||||
Proceeds from sales of common stock and warrants, net of expenses
|
11,779,525
|
|
|
106,791
|
|
||
Proceeds from sales of Series B Convertible Preferred Stock, net of expenses
|
4,386,762
|
|
|
—
|
|
||
Proceeds from exercise of warrants
|
1,612,667
|
|
|
—
|
|
||
Payment upon debt extinguishment
|
(175,381
|
)
|
|
(1,613,067
|
)
|
||
Repayments of long-term debt
|
—
|
|
|
(15,000,000
|
)
|
||
Repayments of equipment line of credit
|
(1,200,033
|
)
|
|
(313,052
|
)
|
||
Net cash provided by (used in) financing activities
|
16,403,540
|
|
|
(16,819,328
|
)
|
||
Effect of exchange rate changes on cash and cash equivalents
|
—
|
|
|
2,411
|
|
||
Net change in cash and cash equivalents
|
10,260,186
|
|
|
(6,131,203
|
)
|
||
Cash and cash equivalents—Beginning of period
|
8,225,764
|
|
|
13,915,094
|
|
||
Cash and cash equivalents—End of period
|
$
|
18,485,950
|
|
|
$
|
7,783,891
|
|
|
|
|
|
||||
Supplementary disclosure of cash flow activity:
|
|
|
|
||||
Cash paid for taxes
|
$
|
800
|
|
|
$
|
800
|
|
Cash paid for interest
|
$
|
22,482
|
|
|
$
|
629,952
|
|
Supplemental disclosure of non-cash investing and financing activities:
|
|
|
|
||||
Preferred stock dividend payable on Series A Convertible Preferred Stock
|
$
|
12,120
|
|
|
$
|
12,120
|
|
Deemed dividend recognized for beneficial conversion features of Series B Convertible Preferred Stock issuance
|
$
|
2,769,533
|
|
|
$
|
—
|
|
Common stock issued upon conversion of Series B Convertible Preferred Stock
|
$
|
321
|
|
|
$
|
—
|
|
•
|
Seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; and
|
•
|
Relinquish licenses or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize themselves, on unfavorable terms.
|
•
|
Raising capital through public and private equity offerings;
|
•
|
Introducing operation and business development initiatives to bring in new revenue streams;
|
•
|
Reducing operating costs by identifying internal synergies; and
|
•
|
Engaging in strategic partnerships.
|
|
Three Months
Ended June 30, |
|
Six Months
Ended June 30, |
||||||||||||
|
2018
|
|
2017
|
|
2018
|
|
2017
|
||||||||
Numerator: Net loss attributable to common shareholders
|
$
|
(6,522,548
|
)
|
|
$
|
(8,051,871
|
)
|
|
$
|
(11,314,785
|
)
|
|
$
|
(18,057,468
|
)
|
Adjustment for gain from change in fair value of derivative financial instruments
—
warrants
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Net loss used for diluted loss per share
|
$
|
(6,522,548
|
)
|
|
$
|
(8,051,871
|
)
|
|
$
|
(11,314,785
|
)
|
|
$
|
(18,057,468
|
)
|
Denominator for basic and diluted net loss per share:
|
|
|
|
|
|
|
|
||||||||
Weighted-average shares used to compute basic loss per share
|
7,423,463
|
|
|
2,582,645
|
|
|
6,026,345
|
|
|
2,581,372
|
|
||||
Adjustments to reflect assumed exercise of warrants
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Weighted-average shares used to compute diluted net loss per share
|
7,423,463
|
|
|
2,582,645
|
|
|
6,026,345
|
|
|
2,581,372
|
|
||||
Net loss per share attributable to common stockholders:
|
|
|
|
|
|
|
|
||||||||
Basic
|
$
|
(0.88
|
)
|
|
$
|
(3.12
|
)
|
|
$
|
(1.88
|
)
|
|
$
|
(7.00
|
)
|
Diluted
|
$
|
(0.88
|
)
|
|
$
|
(3.12
|
)
|
|
$
|
(1.88
|
)
|
|
$
|
(7.00
|
)
|
|
June 30,
|
||||
|
2018
|
|
2017
|
||
Options to purchase Common Stock
|
540,998
|
|
|
299,096
|
|
Warrants to purchase Common Stock
|
22,189,533
|
|
|
360,740
|
|
Restricted Stock Units
|
12,401
|
|
|
121,025
|
|
Series A Convertible Preferred Stock
|
5,261
|
|
|
5,261
|
|
Series B Convertible Preferred Stock
|
5,650,000
|
|
|
—
|
|
|
28,398,193
|
|
|
786,122
|
|
|
Fair Value Measurements at
June 30, 2018 |
||||||||||||||
|
Quoted Prices in Active Markets for Identical Assets and Liabilities
(Level 1)
|
|
Significant Other Observable Inputs
(Level 2)
|
|
Significant Unobservable Inputs
(Level 3)
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Money market fund (1)
|
$
|
18,469,871
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
18,469,871
|
|
Total Assets
|
$
|
18,469,871
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
18,469,871
|
|
Liabilities:
|
|
|
|
|
|
|
|
||||||||
Derivative financial instruments
—
warrants
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
67,847
|
|
|
$
|
67,847
|
|
Total Liabilities
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
67,847
|
|
|
$
|
67,847
|
|
|
Fair Value Measurements at
December 31, 2017 |
||||||||||||||
|
Quoted Prices in Active Markets for Identical Assets and Liabilities
(Level 1)
|
|
Significant Other Observable Inputs
(Level 2)
|
|
Significant Unobservable Inputs
(Level 3)
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Money market fund (1)
|
$
|
8,309,964
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
8,309,964
|
|
Total Assets
|
$
|
8,309,964
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
8,309,964
|
|
Liabilities:
|
|
|
|
|
|
|
|
||||||||
Derivative financial instruments
—
warrants
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
649,387
|
|
|
$
|
649,387
|
|
Total Liabilities
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
649,387
|
|
|
$
|
649,387
|
|
|
Description
|
|
Balance at
December 31, 2017 |
|
Realized (gains) or losses
|
|
Balance at
June 30, 2018 |
||||||
Derivative financial instruments
—
warrants
|
|
$
|
649,387
|
|
|
$
|
(581,540
|
)
|
|
$
|
67,847
|
|
|
As of June 30,
2018 |
|
As of December 31,
2017 |
||||
Furniture and office equipment
|
$
|
1,072,156
|
|
|
$
|
1,076,709
|
|
Leasehold improvements
|
1,994,514
|
|
|
1,994,514
|
|
||
Laboratory equipment
|
912,940
|
|
|
1,426,581
|
|
||
|
3,979,610
|
|
|
4,497,804
|
|
||
Less—accumulated depreciation and amortization
|
(2,175,689
|
)
|
|
(2,071,492
|
)
|
||
Property and equipment, net
|
$
|
1,803,921
|
|
|
$
|
2,426,312
|
|
|
Six Months Ended June 30,
|
||||
|
2018
|
|
2017
|
||
Estimated fair value of Trovagene common stock
|
0.77-4.20
|
|
|
13.80-15.12
|
|
Expected warrant term
|
0.5-5.1 years
|
|
|
1.5-1.8 years
|
|
Risk-free interest rate
|
1.76-2.71%
|
|
|
1.27-1.38%
|
|
Expected volatility
|
91-131%
|
|
|
98-109%
|
|
Dividend yield
|
0
|
%
|
|
0
|
%
|
Date
|
|
Description
|
|
Number of Warrants
|
|
Derivative
Instrument
Liability
|
|||
December 31, 2017
|
|
Balance of derivative financial instruments
—
warrants liability
|
|
467,584
|
|
|
$
|
649,387
|
|
|
|
Change in fair value of derivative financial instruments
—
warrants during the period recognized as a gain in the condensed consolidated statements of operations
|
|
—
|
|
|
(581,540
|
)
|
|
June 30, 2018
|
|
Balance of derivative financial instruments
—
warrants liability
|
|
467,584
|
|
|
$
|
67,847
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2018
|
|
2017
|
|
2018
|
|
2017
|
||||||||
Included in research and development expense
|
$
|
111,812
|
|
|
$
|
206,463
|
|
|
$
|
507,521
|
|
|
$
|
578,663
|
|
Included in cost of revenue
|
(9,143
|
)
|
|
15,209
|
|
|
30,488
|
|
|
41,365
|
|
||||
Included in selling, general and administrative expense
|
118,631
|
|
|
600,069
|
|
|
1,089,422
|
|
|
1,201,378
|
|
||||
Benefit from restructuring
|
—
|
|
|
(46,356
|
)
|
|
—
|
|
|
(125,222
|
)
|
||||
Total stock-based compensation expense
|
$
|
221,300
|
|
|
$
|
775,385
|
|
|
$
|
1,627,431
|
|
|
$
|
1,696,184
|
|
|
Six Months Ended June 30,
|
||||
|
2018
|
|
2017 (1)
|
||
Risk-free interest rate
|
2.43
|
%
|
|
—
|
%
|
Dividend yield
|
0
|
%
|
|
0
|
%
|
Expected volatility
|
90.32
|
%
|
|
—
|
%
|
Expected term
|
5.2 years
|
|
|
0.0 years
|
|
|
|
Total Options
|
|
Weighted-Average
Exercise Price
Per Share
|
|
Intrinsic
Value
|
|||||
Balance outstanding, December 31, 2017
|
374,251
|
|
|
$
|
48.52
|
|
|
$
|
—
|
|
Granted
|
263,077
|
|
|
$
|
3.60
|
|
|
|
|
|
Canceled / Forfeited
|
(95,121
|
)
|
|
$
|
50.17
|
|
|
|
|
|
Expired
|
(1,209
|
)
|
|
$
|
36.00
|
|
|
|
|
|
Balance outstanding, June 30, 2018
|
540,998
|
|
|
$
|
26.41
|
|
|
$
|
—
|
|
Exercisable at June 30, 2018
|
402,488
|
|
|
$
|
31.04
|
|
|
$
|
—
|
|
|
Number of Shares
|
|
Weighted-Average
Grant Date Fair Value
Per Share
|
|
Intrinsic Value
|
|||||
Non-vested RSUs outstanding, December 31, 2017
|
106,200
|
|
|
$
|
17.22
|
|
|
$
|
391,878
|
|
Vested
|
(75,400
|
)
|
|
$
|
14.21
|
|
|
$
|
266,491
|
|
Forfeited
|
(18,399
|
)
|
|
$
|
24.60
|
|
|
|
||
Non-vested RSUs outstanding, June 30, 2018
|
12,401
|
|
|
$
|
24.60
|
|
|
$
|
9,549
|
|
|
Total Warrants (1)
|
|
Weighted-Average
Exercise Price
Per Share
|
|
Weighted-Average
Remaining Contractual
Term (1)
|
|||
Balance outstanding, December 31, 2017
|
1,936,641
|
|
|
$
|
11.34
|
|
|
4.4
|
Granted
|
20,700,000
|
|
|
$
|
1.10
|
|
|
|
Exercised
|
(447,108
|
)
|
|
$
|
3.60
|
|
|
|
Balance outstanding, June 30, 2018
|
22,189,533
|
|
|
$
|
1.94
|
|
|
4.9
|
|
•
|
Complete Phase 1b dose escalation cohorts and identify the recommended Phase 2 dose (“RP2D”) for the Phase 2 continuation trial (dependent upon the number of dose escalation cohorts required to reach the maximum tolerated dose or RP2D of PCM-075).
|
•
|
Provide topline preliminary safety and efficacy data on the combination of PCM-075 + LDAC and the combination of PCM-075 + decitabine in patients treated through the end of 2018.
|
•
|
Present data from the AML trial at the 60
th
annual American Society of Hematology (“ASH”) conference in December 2018.
|
•
|
Initiate the Phase 2 segment of the AML trial, which will enroll 32 patients for continued evaluation of safety and preliminary efficacy of PCM-075 in combination with either LDAC or decitabine (provided the RP2D has been determined in Phase 1b).
|
•
|
Complete enrollment and cycle 1 of treatment of the 3 safety lead-in patients with PCM-075 at 24 mg/m
2
in combination with abiraterone acetate (Zytiga
®
) and prednisone.
|
•
|
Evaluate the three lead-in patients in the mCRPC trial for safety.
|
•
|
Provide topline preliminary safety and efficacy data of PCM-075 in combination with abiraterone acetate (Zytiga
®
) and prednisone in patients treated through the end of 2018.
|
•
|
Announced Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML.
|
•
|
Announced the Start of Recruitment and Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga
®
in Patients with mCRPC.
|
•
|
Announced Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML trial.
|
•
|
Announced Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 AML trial of PCM-075 in AML.
|
•
|
Announced Presentation of Data at American Association for Cancer Research (“AACR”) Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine.
|
•
|
Announced Presentation of data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in AML.
|
•
|
Announced First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low-Dose Cytarabinein AML Trial.
|
•
|
Announced Presentation of Data Showing Synergy of PCM-075 in Combination with Zytiga
®
(abiraterone acetate) in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium.
|
|
Three Months Ended June 30,
|
||||||||||
|
2018
|
|
2017
|
|
Increase (Decrease)
|
||||||
Royalties
|
$
|
52,423
|
|
|
$
|
44,810
|
|
|
$
|
7,613
|
|
Diagnostic services
|
39,345
|
|
|
55,501
|
|
|
(16,156
|
)
|
|||
Clinical research services
|
20,045
|
|
|
1,700
|
|
|
18,345
|
|
|||
Total revenues
|
$
|
111,813
|
|
|
$
|
102,011
|
|
|
$
|
9,802
|
|
|
Three Months Ended June 30,
|
||||||||||
|
2018
|
|
2017
|
|
Increase (Decrease)
|
||||||
Salaries and staff costs
|
$
|
513,331
|
|
|
$
|
291,195
|
|
|
$
|
222,136
|
|
Stock-based compensation
|
111,812
|
|
|
206,463
|
|
|
(94,651
|
)
|
|||
Outside services, consultants and lab supplies
|
1,115,009
|
|
|
217,570
|
|
|
897,439
|
|
|||
Facilities
|
183,327
|
|
|
219,614
|
|
|
(36,287
|
)
|
|||
Travel and scientific conferences
|
20,210
|
|
|
28,861
|
|
|
(8,651
|
)
|
|||
Fees, license and other
|
9,078
|
|
|
18,012
|
|
|
(8,934
|
)
|
|||
Total research and development
|
$
|
1,952,767
|
|
|
$
|
981,715
|
|
|
$
|
971,052
|
|
|
Three Months Ended June 30,
|
||||||||||
|
2018
|
|
2017
|
|
Increase (Decrease)
|
||||||
Salaries and staff costs
|
$
|
1,109,476
|
|
|
$
|
755,171
|
|
|
$
|
354,305
|
|
Board of Directors’ fees
|
121,616
|
|
|
113,501
|
|
|
8,115
|
|
|||
Stock-based compensation
|
118,631
|
|
|
600,069
|
|
|
(481,438
|
)
|
|||
Outside services and consultants
|
276,543
|
|
|
263,810
|
|
|
12,733
|
|
|||
Legal and accounting fees
|
125,033
|
|
|
2,325,239
|
|
|
(2,200,206
|
)
|
|||
Facilities and insurance
|
275,975
|
|
|
350,992
|
|
|
(75,017
|
)
|
|||
Travel and conferences
|
44,041
|
|
|
181,016
|
|
|
(136,975
|
)
|
|||
Fees, license and other
|
79,556
|
|
|
84,354
|
|
|
(4,798
|
)
|
|||
Total selling, general and administrative
|
$
|
2,150,871
|
|
|
$
|
4,674,152
|
|
|
$
|
(2,523,281
|
)
|
|
Three Months Ended June 30,
|
||||||||||
|
2018
|
|
2017
|
|
Increase (Decrease)
|
||||||
Net loss attributable to common shareholders
|
$
|
(6,522,548
|
)
|
|
$
|
(8,051,871
|
)
|
|
$
|
(1,529,323
|
)
|
Net loss per common share — basic
|
$
|
(0.88
|
)
|
|
$
|
(3.12
|
)
|
|
$
|
(2.24
|
)
|
Net loss per common share — diluted
|
$
|
(0.88
|
)
|
|
$
|
(3.12
|
)
|
|
$
|
(2.24
|
)
|
|
|
|
|
|
|
||||||
Weighted average shares outstanding — basic
|
7,423,463
|
|
|
2,582,645
|
|
|
4,840,818
|
|
|||
Weighted average shares outstanding — diluted
|
7,423,463
|
|
|
2,582,645
|
|
|
4,840,818
|
|
|
Three Months Ended June 30,
|
||||||||||
|
2018
|
|
2017
|
|
Increase (Decrease)
|
||||||
Net loss attributable to common shareholders
|
$
|
(6,522,548
|
)
|
|
$
|
(8,051,871
|
)
|
|
$
|
(1,529,323
|
)
|
Adjustment for preferred stock dividend recognized from beneficial conversion features of Series B Convertible Preferred Stock issuance
|
2,769,533
|
|
|
—
|
|
|
2,769,533
|
|
|||
Total net loss attributable to common shareholders
|
$
|
(3,753,015
|
)
|
|
$
|
(8,051,871
|
)
|
|
$
|
1,240,210
|
|
|
|
|
|
|
|
||||||
Net loss per common share — basic and diluted
|
$
|
(0.44
|
)
|
|
$
|
(3.12
|
)
|
|
$
|
(2.68
|
)
|
|
|
|
|
|
|
||||||
Weighted average shares outstanding — basic and diluted
|
7,423,463
|
|
|
2,582,645
|
|
|
4,840,818
|
|
|||
Adjustment for Series B Convertible Preferred Stock
|
1,179,670
|
|
|
—
|
|
|
1,179,670
|
|
|||
Total weighted average shares outstanding — basic and diluted
|
8,603,133
|
|
|
2,582,645
|
|
|
6,020,488
|
|
|
Six Months Ended June 30,
|
||||||||||
|
2018
|
|
2017
|
|
Increase (Decrease)
|
||||||
Royalties
|
$
|
101,478
|
|
|
$
|
110,636
|
|
|
$
|
(9,158
|
)
|
Diagnostic services
|
79,347
|
|
|
84,363
|
|
|
(5,016
|
)
|
|||
Clinical research services
|
31,124
|
|
|
2,050
|
|
|
29,074
|
|
|||
Total revenues
|
$
|
211,949
|
|
|
$
|
197,049
|
|
|
$
|
14,900
|
|
|
Six Months Ended June 30,
|
||||||||||
|
2018
|
|
2017
|
|
Increase (Decrease)
|
||||||
Salaries and staff costs
|
$
|
915,399
|
|
|
$
|
1,166,572
|
|
|
$
|
(251,173
|
)
|
Stock-based compensation
|
507,521
|
|
|
578,663
|
|
|
(71,142
|
)
|
|||
Outside services, consultants and lab supplies
|
1,964,997
|
|
|
852,364
|
|
|
1,112,633
|
|
|||
Facilities
|
374,718
|
|
|
587,515
|
|
|
(212,797
|
)
|
|||
Travel and scientific conferences
|
59,428
|
|
|
44,901
|
|
|
14,527
|
|
|||
Fees, licenses and other
|
14,542
|
|
|
2,031,530
|
|
|
(2,016,988
|
)
|
|||
Total research and development
|
$
|
3,836,605
|
|
|
$
|
5,261,545
|
|
|
$
|
(1,424,940
|
)
|
|
Six Months Ended June 30,
|
||||||||||
|
2018
|
|
2017
|
|
Increase (Decrease)
|
||||||
Salaries and staff costs
|
$
|
1,799,646
|
|
|
$
|
2,176,764
|
|
|
$
|
(377,118
|
)
|
Board of Directors’ fees
|
249,944
|
|
|
227,120
|
|
|
22,824
|
|
|||
Stock-based compensation
|
1,089,422
|
|
|
1,201,378
|
|
|
(111,956
|
)
|
|||
Outside services and consultants
|
467,605
|
|
|
607,430
|
|
|
(139,825
|
)
|
|||
Legal and accounting fees
|
288,053
|
|
|
2,785,921
|
|
|
(2,497,868
|
)
|
|||
Facilities and insurance
|
531,028
|
|
|
620,330
|
|
|
(89,302
|
)
|
|||
Travel and conferences
|
100,498
|
|
|
464,949
|
|
|
(364,451
|
)
|
|||
Fees, license and other
|
129,652
|
|
|
194,884
|
|
|
(65,232
|
)
|
|||
Total selling, general and administrative
|
$
|
4,655,848
|
|
|
$
|
8,278,776
|
|
|
$
|
(3,622,928
|
)
|
|
Six Months Ended June 30,
|
||||||||||
|
2018
|
|
2017
|
|
Increase (Decrease)
|
||||||
Net loss attributable to common shareholders
|
$
|
(11,314,785
|
)
|
|
$
|
(18,057,468
|
)
|
|
$
|
(6,742,683
|
)
|
Net loss per common share — basic
|
$
|
(1.88
|
)
|
|
$
|
(7.00
|
)
|
|
$
|
(5.12
|
)
|
Net loss per common share — diluted
|
$
|
(1.88
|
)
|
|
$
|
(7.00
|
)
|
|
$
|
(5.12
|
)
|
|
|
|
|
|
|
||||||
Weighted average shares outstanding — basic
|
6,026,345
|
|
|
2,581,372
|
|
|
3,444,973
|
|
|||
Weighted average shares outstanding — diluted
|
6,026,345
|
|
|
2,581,372
|
|
|
3,444,973
|
|
|
Six Months Ended June 30,
|
||||||||||
|
2018
|
|
2017
|
|
Increase (Decrease)
|
||||||
Net loss attributable to common shareholders
|
$
|
(11,314,785
|
)
|
|
$
|
(18,057,468
|
)
|
|
$
|
(6,742,683
|
)
|
Adjustment for preferred stock dividend recognized from beneficial conversion features of Series B Convertible Preferred Stock issuance
|
2,769,533
|
|
|
—
|
|
|
2,769,533
|
|
|||
Total net loss attributable to common shareholders
|
$
|
(8,545,252
|
)
|
|
$
|
(18,057,468
|
)
|
|
$
|
(3,973,150
|
)
|
|
|
|
|
|
|
||||||
Net loss per common share — basic and diluted
|
$
|
(1.29
|
)
|
|
$
|
(7.00
|
)
|
|
$
|
(5.71
|
)
|
|
|
|
|
|
|
||||||
Weighted average shares outstanding — basic and diluted
|
6,026,345
|
|
|
2,581,372
|
|
|
3,444,973
|
|
|||
Adjustment for Series B Convertible Preferred Stock
|
593,094
|
|
|
—
|
|
|
593,094
|
|
|||
Total weighted average shares outstanding — basic and diluted
|
6,619,439
|
|
|
2,581,372
|
|
|
4,038,067
|
|
Exhibit
Number
|
|
Description of Exhibit
|
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Labels Linkbase
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase
|
|
TROVAGENE, INC.
|
|
|
|
|
August 3, 2018
|
By:
|
/s/ Thomas Adams
|
|
|
Thomas Adams
|
|
|
Interim Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)
|
a)
|
he has read this Agreement;
|
b)
|
he has been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of his own choice or has elected not to retain legal counsel;
|
c)
|
he understands the terms and consequences of this Agreement and of the releases it contains; and
|
d)
|
he is fully aware of the legal and binding effect of this Agreement.
|
|
WILLIAM WELCH, an individual
|
Dated:
July 30
, 2018
|
/s/ William Welch
|
|
William Welch
|
|
TROVAGENE, INC., a Delaware Corporation
|
Dated:
July 30
, 2018
|
/s/ Thomas Adams
|
|
Thomas Adams
Interim Chief Executive Officer
|
1.
|
I have reviewed this quarterly report on Form 10-Q of Trovagene, Inc. (the “Registrant”);
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a.
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
|
b.
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c.
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d.
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions);
|
a.
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b.
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
August 3, 2018
|
/s/ Thomas Adams
|
|
Thomas Adams
|
|
Interim Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)
|
August 3, 2018
|
/s/ Thomas Adams
|
|
Thomas Adams
|
|
Interim Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)
|